Stock Events

Stock Events

Tourmaline Bio 

$47.98
65
+$0.00+0% Monday 20:00
+$0.01+0.02%Monday 23:11Pre-market

Statistics

Day High
47.98
Day Low
47.98
52W High
48.27
52W Low
11.56
Volume
779,870
Avg. Volume
925,778
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Oct 23
$15.12
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

6NovExpected
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
-0.95
-0.81
-0.68
-0.55
Expected EPS
-0.9461
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-73.21MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is a competitor because it also focuses on developing gene-based therapies, similar to Tourmaline Bio's focus on RNA-based therapies, making them direct competitors in the genetic medicine space.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the genome editing field, directly competing with Tourmaline Bio in the development of genetic treatments and therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is a leading developer of CRISPR/Cas9 gene-editing therapies, competing with Tourmaline Bio in the broader genetic medicine and therapy market.
Beam Therapeutics
BEAM
Mkt Cap3.03B
Beam Therapeutics competes with Tourmaline Bio by focusing on base editing, a novel form of gene editing, positioning itself as a competitor in the genetic therapy industry.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is a competitor due to its focus on RNA interference (RNAi) therapies, which overlaps with Tourmaline Bio's focus on RNA-based therapeutic approaches.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals competes with Tourmaline Bio by developing RNA-targeted therapies, making it a direct competitor in the RNA therapy space.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on developing gene therapies for rare diseases, positioning it as a competitor to Tourmaline Bio in the niche market of genetic treatments.
Voyager Therapeutics
VYGR
Mkt Cap218.13M
Voyager Therapeutics competes with Tourmaline Bio in the gene therapy space, focusing on severe neurological diseases, which may overlap with Tourmaline Bio's therapeutic areas.

About

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Show more...
CEO
Dr. Sandeep C. Kulkarni M.D.
Employees
74
Country
United States
ISIN
US89157D1054

Listings

0 Comments

Share your thoughts

FAQ

What is Tourmaline Bio stock price today?▼
The current price of TRML is $47.98 USD — it has increased by +0% in the past 24 hours. Watch Tourmaline Bio stock price performance more closely on the chart.
What is Tourmaline Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Tourmaline Bio stocks are traded under the ticker TRML.
Is Tourmaline Bio stock price growing?▼
TRML stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Tourmaline Bio has showed a +79.43% increase.
What is Tourmaline Bio revenue for the last year?▼
Tourmaline Bio revenue for the last year amounts to 0 USD.
What is Tourmaline Bio net income for the last year?▼
TRML net income for the last year is -73.21M USD.
Does Tourmaline Bio pay dividends?▼
Yes, TRML dividends are paid en. The last dividend per share was 15.12 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Tourmaline Bio have?▼
As of September 06, 2026, the company has 74 employees.
In which sector is Tourmaline Bio located?▼
Tourmaline Bio operates in the Health & Wellness sector.
When did Tourmaline Bio complete a stock split?▼
The last stock split for Tourmaline Bio was on October 20, 2023 with a ratio of 1:10.
Where is Tourmaline Bio headquartered?▼
Tourmaline Bio is headquartered in New York, United States.